1 / 18

COPD (2) (1)

Everything you need to know about COPD

Alex51
Download Presentation

COPD (2) (1)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. COPD CHRONIC OBSTRUCTIVE PULMONARY DISEASE

  2. Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

  3. Plan 1. Introduction: relevance, purpose; 2. Main part: definition, etiology, pathobiology, pathology, diagnosis, stages, management, pharmacologic and non- pharmaclogic treatment; 3. Conclusions, questions and references.

  4. COPD Etiology, Pathobiology & Pathology

  5. Factors that influence disease progression:

  6. Diagnosis and Initial Assessment ► COPD should be considered in any patient who has dyspnea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. ► Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation. ► The goals of COPD assessment are to determine the level of airflow limitation, the impact of disease on the patient’s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy. ► Concomitant chronic diseases occur frequently in COPD patients, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety, and lung cancer. These comorbidities should be actively sought and treated appropriately when present as they can influence mortality and hospitalizations independently.

  7. Diagnosis

  8. Diagnosis

  9. Choice of thresholds ►COPD Assessment Test (CAT TM) ►Chronic Respiratory Questionnaire (CCQ® ) ►St George’s Respiratory Questionnaire (SGRQ) ►Chronic Respiratory Questionnaire (CRQ) ►Modified Medical Research Council (mMRC) questionnaire

  10. ABCD Assessment Tool

  11. Management of Stable COPD ►The management strategy for stable COPD should be predominantly based on the individualized assessment of symptoms and future risk of exacerbations. ►All individuals who smoke should be strongly encouraged and supported to quit. ►The main treatment goals are reduction of symptoms and future risk of exacerbations. ►Management strategies are not limited to pharmacologic treatments, and should be complemented by appropriate non- pharmacologic interventions.

  12. Treatment of COPD

  13. Treatment of Stable COPD © 2017 Global Initiative for Chronic Obstructive Lung Disease

  14. Non-Pharmacologic Treatment

  15. Conclusions (Some statistics) •The National Heart, Lung, and Blood Institute (NHLBI) estimates that 12 million adults have COPD, and another 12 million are undiagnosed or developing COPD •Estimated that over 210 million people worldwide have COPD •COPD cost the U.S. economy about $32.1 billion, in direct and indirect costs in 2002 •A person with COPD dies every five minutes in the world •COPD will be the third leading cause of death in the world by 2030

  16. Questions 2. In GOLD’s refined assessment criteria, what is required for a diagnosis of COPD? A. Spirometry B. Lung diffusion capacity test C. Chest x-ray or chest CT scan D. Arterial blood gas test 1. GOLD’s updated definition for COPD emphasizes which developmental factors? A. Respiratory symptoms B. Emphysema and chronic bronchitis C. Lung tissue and airway abnormalities D. A, B, and C E. Aand C but not B

  17. 4. In GOLD’s updated guideline, traditional COPD “ABCD” disease severity groups are further defined by the addition of: A. Respiratory symptoms subgroups B. Exacerbation history subgroups C. Spirometric grade subgroups D. Smoking cessation success rates 3. Treatment of stable COPD is now based on disease impact (symptom burden, activity limitations) and risk of progression as determined by exacerbations. True or false? A. True B. False

  18. References •The World Health Organization http://www.who.int/mediacentre/factsheets/fs315/en/ •The COPD Foundation http://www.copdfoundation.org/ •The US Department of Health and Human Services http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_WhatIs.html •National Heart Lung and Blood Institute http://www.nhlbi.nih.gov/health/public/lung/other/copd_breathe.htm •Center for Disease Control and Prevention http://www.cdc.gov/

More Related